Naylor Stuart sold $409K of MGTX
Naylor Stuart (CHIEF SCI OFCR, OPHTHALMOLOGY) sold 27,659 shares of MeiraGTx Holdings plc (MGTX) at an average of $14.80 ($13.86–$14.90, $0.41M total) across 2 trades on 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the reported open-market sale by the company’s Chief Scientific Officer (ophthalmology) totaling ~$409.5K across two trades on 2026-07-07, executed under a 10b5-1 plan.
Market read
Insider selling is disclosed, but the 10b5-1 context suggests limited incremental fundamental information.
What to watch
Traders may over-weight insider sales; without accompanying changes in guidance, trial results, or financing terms, the filing is unlikely to drive fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for MeiraGTx Holdings plc (MGTX).
Ticker impact
MeiraGTx insider Naylor Stuart sold 27,659 shares in open-market trades on 2026-07-07 for ~$409.5K under a 10b5-1 plan.
Likely modest, short-lived sentiment impact; no clear directional catalyst from the filing alone.
The disclosure is a Form 4 insider transaction (open-market sale) with a pre-arranged 10b5-1 plan; such sales are often non-informational, though they can still influence trading psychology.
Market effects
Minimal; this is company-specific insider activity rather than a sector/regulatory/clinical catalyst.
Minimal; no cross-market linkage described beyond the issuer’s filing.
Low; no deal, trial, or regulatory action affecting broader markets is mentioned.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerMeiraGTx Holdings plc
Subject of the Form 4 insider transaction disclosure.
- insiderNaylor Stuart
Chief Scientific Officer, Ophthalmology; sold 27,659 shares on 2026-07-07.
- trading mechanism10b5-1 plan
Pre-arranged plan noted as Yes, which typically reduces informational content of sales.
